CD19 and diffuse large B-cell lymphoma: Based on these findings, a clinical trial is underway in which patients with refractory or relapsed DLBCL, FL, or mantle cell lymphoma following CD19-specific CAR-T cell infusion are treated with pembrolizumab in an attempt to reactivate exhausted CAR-T cells (NCT02650999; Table 1).